MCID: SJG008
MIFTS: 59

Sjogren Syndrome

Categories: Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Sjogren Syndrome

MalaCards integrated aliases for Sjogren Syndrome:

Name: Sjogren Syndrome 57 12 53 37
Sjogren's Syndrome 12 25 43 44 15 73
Sicca Syndrome 57 12 53 25 73
Keratoconjunctivitis Sicca 25 73
Sjogren-Gougerot Syndrome 53 25
Keratoconjunctivitis Sicca-Xerostomia 25
Secreto-Inhibitor-Xerodermostenosis 25
Dacryosialoadenopathia Atrophicans 25
Gougerot-Houwer-Sjogren Syndrome 25
Gougerot-Sjogren Syndrome 25
Sj�gren's Syndrome 76
Sjögren's Syndrome 54
Dry Eye Syndromes 73
Sjogrens Syndrome 55
Xerodermosteosis 12
Sjögren Syndrome 25

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
sjogren syndrome:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Sjogren Syndrome

MedlinePlus : 43 Sjogren's syndrome is an autoimmune disease. This means that your immune system attacks parts of your own body by mistake. In Sjogren's syndrome, it attacks the glands that make tears and saliva. This causes a dry mouth and dry eyes. You may have dryness in other places that need moisture, such as your nose, throat, and skin. Sjogren's can also affect other parts of the body, including your joints, lungs, kidneys, blood vessels, digestive organs, and nerves. Most people with Sjogren's syndrome are women. It usually starts after age 40. It is sometimes linked to other diseases such as rheumatoid arthritis and lupus. To make a diagnosis, doctors may use a medical history, physical exam, certain eye and mouth tests, blood tests, and biopsies. Treatment focuses on relieving symptoms. It can differ for each person; it depends on what parts of the body are affected. It may include artificial tears for dye eyes and sucking on sugar-free candy or drinking water often for a dry mouth. Medicines may help with severe symptoms. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Sjogren Syndrome, also known as sjogren's syndrome, is related to aplasia of lacrimal and salivary glands and dacryoadenitis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Sjogren Syndrome is LOC105373557 (Uncharacterized LOC105373557), and among its related pathways/superpathways are Toll-like receptor signaling pathway and JAK-STAT signaling pathway. The drugs Prednisone and Calcium Carbonate have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and skin, and related phenotypes are abnormality of metabolism/homeostasis and autoimmunity

Disease Ontology : 12 An autoimmune hypersensitivity disease that involves attack of immune cells which destroy the exocrine glands that produce tears and saliva.

Genetics Home Reference : 25 Sjögren syndrome is a disorder whose main features are dry eyes and a dry mouth. The condition typically develops gradually beginning in middle adulthood, but it can occur at any age.

NIH Rare Diseases : 53 Sjögren syndrome is an autoimmune disorder in which immune cells attack and destroy the glands that produce tears and saliva. Sjögren syndrome is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. The hallmark symptoms of Sjögren syndrome are dry mouth and dry eyes. In addition, Sjogren syndrome may cause skin, nose, and vaginal dryness. It also may affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain. Treatment focuses on the symptoms in each person and may include moisture replacement therapies, nonsteroidal anti-inflammatory drugs and, in severe cases, corticosteroids or immunosuppressive drugs.

OMIM : 57 Sjogren syndrome is an autoimmune disease that mainly affects the exocrine glands. It is clinically characterized by keratoconjunctivitis sicca and xerostomia (Goransson et al., 2006). See 200400 for association of Sjogren syndrome with achalasia in sisters. (270150)

Wikipedia : 76 Sjögren syndrome (SjS, SS) is a long-term autoimmune disease that affects the body''s moisture-producing... more...

Related Diseases for Sjogren Syndrome

Diseases in the Sjogren Syndrome family:

Sjogren's Syndrome, Juvenile, Secondary to Autoimmune Disease Primary Sjögren Syndrome

Diseases related to Sjogren Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 aplasia of lacrimal and salivary glands 31.3 AQP5 HSPG2 LTF SPTAN1
2 dacryoadenitis 30.3 AQP5 HSPG2
3 lupus erythematosus 30.0 APOH SSB TNFSF4 TRIM21 TROVE2
4 connective tissue disease 29.9 APOH SSB TNFSF13B
5 hyperglobulinemic purpura 29.9 HSPG2 TRIM21
6 collagen disease 29.8 SSB TRIM21 TROVE2
7 rheumatic disease 29.8 APOH SSB TRIM21
8 systemic lupus erythematosus 29.6 APOH FASLG SSB TNFSF13B TNFSF4 TRIM21
9 sialadenitis 29.3 AQP5 HSPG2 TNFSF13B TRIM21 TROVE2
10 marinesco-sjogren syndrome 12.6
11 primary sjögren syndrome 11.4
12 systemic scleroderma 11.3
13 retrovirus-associated myelopathy 11.3
14 tenorio syndrome 11.2
15 congenital cataracts, facial dysmorphism, and neuropathy 11.0
16 autoimmune disease 6 11.0
17 mikulicz disease 11.0
18 felty syndrome 11.0
19 gillespie syndrome 11.0
20 collagenous gastritis 11.0
21 graft-versus-host disease 10.3
22 neonatal lupus erythematosus 10.2 SPTAN1 TRIM21
23 heart block, congenital 10.2 TRIM21 TROVE2
24 xerophthalmia 10.2 HSPG2 TRIM21
25 corneal disease 10.2
26 chlamydia 10.2
27 uveitis 10.2
28 ectropion 10.2
29 rosacea 10.2
30 achalasia 10.2
31 chronic graft versus host disease 10.2
32 acute retrobulbar neuritis 10.1 B2M TRIM21
33 lymphoma 10.1
34 functional colonic disease 10.1 B2M HSPG2
35 immune system disease 10.0 APOH SSB TNFSF13B TRIM21
36 small intestine lymphoma 10.0 B2M SIL1
37 autoimmune disease 10.0
38 otitis media 10.0
39 autoimmune disease 1 10.0
40 human immunodeficiency virus type 1 10.0
41 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
42 microvascular complications of diabetes 5 10.0
43 diabetes mellitus 10.0
44 keratoconus 10.0
45 cutaneous lupus erythematosus 10.0
46 erythema multiforme 10.0
47 ocular albinism 10.0
48 sleep apnea 10.0
49 pleurisy 10.0
50 superficial keratitis 10.0

Comorbidity relations with Sjogren Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hypothyroidism Ichthyosis Vulgaris
Osteoporosis Postinflammatory Pulmonary Fibrosis
Rheumatoid Arthritis Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Sjogren Syndrome:



Diseases related to Sjogren Syndrome

Symptoms & Phenotypes for Sjogren Syndrome

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Mouth:
xerostomia

Immunology:
autoimmune disease

Head And Neck Eyes:
xerophthalmia, more severe in men

Skeletal:
rheumatoid arthritis

Genitourinary Kidneys:
interstitial nephritis


Clinical features from OMIM:

270150

Human phenotypes related to Sjogren Syndrome:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 abnormality of metabolism/homeostasis 32 HP:0001939
2 autoimmunity 32 HP:0002960
3 keratoconjunctivitis sicca 32 HP:0001097
4 xerostomia 32 HP:0000217
5 rheumatoid arthritis 32 HP:0001370
6 tubulointerstitial nephritis 32 HP:0001970

UMLS symptoms related to Sjogren Syndrome:


back pain, sciatica, muscle cramp, eye manifestations, dryness of eye

MGI Mouse Phenotypes related to Sjogren Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 B2M FASLG HSPG2 LTF SSB TNFSF13B

Drugs & Therapeutics for Sjogren Syndrome

Drugs for Sjogren Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 187)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Not Applicable 53-03-2 5865
2
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 1 6055-19-2, 50-18-0 2907
5
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
6
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Not Applicable 9004-61-9 53477741
7 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
8
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
9
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2 1177-87-3
11
Tacrolimus Approved, Investigational Phase 4,Phase 1 104987-11-3 445643 439492
12
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 5881
13
Betaine Approved, Nutraceutical Phase 4,Not Applicable 107-43-7 247
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
15
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
16 Gallopamil Investigational Phase 4 16662-47-8
17 Rebamipide Investigational Phase 4,Phase 2,Not Applicable 90098-04-7
18 Calcineurin Inhibitors Phase 4,Phase 2,Phase 1
19 Anti-Ulcer Agents Phase 4,Phase 2,Not Applicable
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Not Applicable
22 Hormones Phase 4,Phase 2,Not Applicable
23 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 glucocorticoids Phase 4,Phase 2,Not Applicable
25 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Cyclosporins Phase 4,Phase 2,Not Applicable
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antifungal Agents Phase 4,Phase 2
30 Hormone Antagonists Phase 4,Phase 2,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 2,Not Applicable
32 Antacids Phase 4,Phase 2,Not Applicable
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
34 Gastrointestinal Agents Phase 4,Phase 2,Phase 1,Not Applicable
35 Calcium, Dietary Phase 4,Not Applicable
36 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
37 DHEA (Dehydroepiandrosterone) Phase 4,Phase 2
38 Vaccines Phase 4,Not Applicable
39 Muscarinic Agonists Phase 4
40 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable
41 Autonomic Agents Phase 4,Phase 2
42 Cholinergic Agents Phase 4
43 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
44 Antioxidants Phase 4,Phase 2,Phase 3,Not Applicable
45 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Viscosupplements Phase 4,Phase 3
49 Listerine Phase 4,Not Applicable
50 Anticoagulants Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
2 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Effect of Pilocarpine in Patients With Xerostomia Unknown status NCT02982577 Phase 4 Pilocarpine
5 Quality of Life and Sjögren Syndrome Completed NCT03578900 Phase 4 Xeros;Citric Acid based Mouthwash
6 Comparison Between Rebamipide 2% Versus Autologous Serum Completed NCT03608761 Phase 4 Rebamipide
7 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed NCT00631358 Phase 4 Maxidex
8 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
9 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
10 A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment Completed NCT00438048 Phase 4 Artificial Saliva
11 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
12 Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome Recruiting NCT03319420 Phase 4 LO2A eye drops;Systane Ultra UD
13 Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Recruiting NCT03540823 Phase 4
14 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease Active, not recruiting NCT03762824 Phase 4
15 Immune Profile of Saliva and Serum of Patients With Primary Sjögren´s Syndrome Not yet recruiting NCT03711214 Phase 4
16 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
17 Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Unknown status NCT01782235 Phase 2, Phase 3 Tocilizumab;Placebo
18 Treatment of Salivary Gland Hypofunction With Neuro- Electrostimulation Unknown status NCT01174329 Phase 2, Phase 3
19 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye Unknown status NCT02257957 Phase 3 PRP injection;Standard care Hyaluronic acid eye drops
20 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
21 Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood Unknown status NCT02153515 Phase 3
22 Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome Completed NCT00632866 Phase 3 Hydroxychloroquine;Placebo
23 Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Completed NCT01601028 Phase 3 Hydroxychloroquine;Placebo
24 A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503163 Phase 3 KCT-0809 ophthalmic solution
25 A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Completed NCT02503189 Phase 3 KCT-0809 ophthalmic solution;Placebo
26 Tolerance and Efficacy of Rituximab in Sjogren's Disease Completed NCT00740948 Phase 2, Phase 3 Rituximab (mabthera) Injection;Placebo: NaCl 0.9% or Glucose 5%
27 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
28 Preventive IVIG Therapy for Congenital Heart Block Completed NCT00460928 Phase 2, Phase 3 intravenous immune globulin (IVIG)
29 Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Recruiting NCT02067910 Phase 3 Abatacept SC
30 RESET Trial - Part 1 (Followed by Reset Trial - Part 2) - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS) Recruiting NCT03445650 Phase 3 ADX-102 1% Topical Dermal Cream (reproxalap);Vehicle of ADX-102 Topical Dermal Cream
31 A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome Active, not recruiting NCT02915159 Phase 3
32 Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Enrolling by invitation NCT03436576 Phase 3 Autologous Serum 20%;Autologous Serum 50%
33 Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies Not yet recruiting NCT03700138 Phase 3 Privigen® 100mg/ml at the dose of 2g/kg of body weight;NaCl 0,9%
34 An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome Terminated NCT02503176 Phase 3 KCT-0809 ophthalmic solution
35 Effect of Saliva Substitutes on Dental Hard Tissues in Situ Terminated NCT01165970 Phase 2, Phase 3 Glandosane
36 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
37 Study of Iguratimod in Sjögren's Syndrome Unknown status NCT03023592 Phase 1, Phase 2 Iguratimod
38 Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome Unknown status NCT02855658 Phase 2 SS-1;Placebo
39 Allogeneic Mesenchymal Stem Cells Transplantation for Primary Sjögren's Syndrome (pSS) Unknown status NCT00953485 Phase 1, Phase 2
40 Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome Unknown status NCT02110446 Phase 2 SS-1;Placebo
41 Acupuncture for Primary Sjögren Syndrome Unknown status NCT02691377 Phase 2
42 Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome Unknown status NCT02691949 Phase 2 Mycophenolate mofetil
43 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Completed NCT02291029 Phase 2 CFZ533 active - Cohort 1;CFZ533 placebo- Cohort 1;CFZ533 active - Cohort 2;CFZ533 placebo - Cohort 2;CFZ533 active -Cohort 3;CFZ533 active - Cohort 3
44 Low Dose Cyclosporin A in Primary Sjögren Syndrome Completed NCT01693393 Phase 2 Cyclosporine A
45 A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome Completed NCT02701985 Phase 2 Placebo;RO5459072
46 PD of VAY736 in Patients With Primary Sjögren's Syndrome Completed NCT02149420 Phase 2 VAY736;Placebo
47 Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Completed NCT02775916 Phase 2 CDZ173;Placebo
48 A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome Completed NCT03247686 Phase 2 RSLV-132;Placebo
49 A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Completed NCT02334306 Phase 2
50 A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome Completed NCT02464319 Phase 2 hrIL-2 active;hrIL-2 placebo

Search NIH Clinical Center for Sjogren Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: sjogren's syndrome

Genetic Tests for Sjogren Syndrome

Anatomical Context for Sjogren Syndrome

MalaCards organs/tissues related to Sjogren Syndrome:

41
Eye, Salivary Gland, Skin, Lung, Testes, Kidney, Thyroid

Publications for Sjogren Syndrome

Articles related to Sjogren Syndrome:

(show top 50) (show all 1695)
# Title Authors Year
1
Neuroprotective modulation of the unfolded protein response in Marinesco-Sjögren syndrome: PERK signaling inhibition and beyond. ( 30531072 )
2019
2
Role of Salivary Immune Parameters in Patients With Primary Sjögren's Syndrome. ( 30215233 )
2019
3
Detection of SSA and SSB Antibodies Associated with Primary Sjögren's Syndrome Using Enzyme-Linked Immunosorbent Assay. ( 30539582 )
2019
4
Survey of Ophthalmologists Regarding Practice Patterns for Dry Eye and Sjogren Syndrome. ( 29369232 )
2018
5
Sjogren Syndrome and Non-Sjogren Sicca Syndrome: Do They Affect the Vulva? ( 29406358 )
2018
6
Fibrillary Glomerulonephritis in a Patient with Sjogren's Syndrome. ( 29922524 )
2018
7
Primary Sjogren syndrome diagnosed simultaneously with localized amyloidosis of the lacrimal gland: A case report. ( 29879064 )
2018
8
Remission of Sjogren's Syndrome after Roux-en-Y Gastric Bypass for Morbid Obesity. ( 29248981 )
2018
9
Gastrointestinal and Hepatic Disease in Sjogren Syndrome. ( 29149922 )
2018
10
Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome. ( 29276674 )
2018
11
Pleuritis associated with primary Sjogren syndrome. ( 29321929 )
2018
12
Unexplained cough: it is time to rule out Sjogren's syndrome. ( 29388084 )
2018
13
Hypokalemic Paralysis Due to Primary Sjogren Syndrome. ( 29911048 )
2018
14
Polyvalent immunoglobulins with vitamin D3 and vitamin B12 in the treatment of Sjogren's syndrome in a vegetarian with stomatitis, glossodynia, xerostomia, and elevated antinuclear antibodies: Case reporta8c. ( 29231165 )
2018
15
Clinical periodontal status and inflammatory cytokines in primary sjogren syndrome and rheumatoid artritis. ( 29752727 )
2018
16
Acute motor and sensory axonal neuropathy associated with Sjögren's syndrome. ( 30335268 )
2018
17
Nodular Pulmonary Amyloidosis: A Manifestation of Sjögren's Syndrome. ( 30210893 )
2018
18
Increased risk of aortic aneurysm and dissection in patients with Sjögren's syndrome: a nationwide population-based cohort study in Taiwan. ( 30244213 )
2018
19
Corrigendum to "Comparative analysis of novel autoantibody isotypes against citrullinatedinter-alpha-trypsin inhibitor heavy chain 3 (ITIH3) 542-556 peptide in serum from Taiwanese females with rheumatoid arthritis, primary Sjögren's syndrome and secondary Sjögren's syndrome in rheumatoid arthritis" [J Proteomics 141: (2016) 1-11]. ( 30553786 )
2018
20
DRESS/DIHS caused by levofloxacin in a patient with systemic scleroderma, rheumatoid arthritis, and Sjogren syndrome. ( 30484869 )
2018
21
Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. ( 30408585 )
2018
22
Anti-citrullinated protein antibodies and arthritis in Sjögren's syndrome: a systematic review and meta-analysis. ( 30270696 )
2018
23
Association of Anti-Ro/Sjögren's syndrome type A Antibodies and Complete Atrioventricular Block in an Adult With Sjögren's Syndrome. ( 30207577 )
2018
24
Autoimmune autonomic ganglionopathy associated with Sjögren's syndrome presenting with recurrent abdominal distension. ( 30279247 )
2018
25
Deciphering Molecular and Phenotypic Changes Associated with Early Autoimmune Disease in the Aire-Deficient Mouse Model of Sjögren's Syndrome. ( 30453645 )
2018
26
Constrictive Bronchiolitis in Patients With Primary Sjögren Syndrome. ( 29596206 )
2018
27
Primary Sjögren's syndrome and bronchiolitis. An unusual association. ( 28268160 )
2018
28
Parotid abscess secondary to brucellosis in a patient with primary Sjögren's syndrome. ( 30501853 )
2018
29
Sjögren's syndrome concurrent with protein-losing gastroenteropathy with secondary systemic capillary leak syndrome : A case report. ( 30214773 )
2018
30
Corneal perforation in undiagnosed Sjögren's syndrome following topical NSAID and steroid drops post routine cataract extraction. ( 30042108 )
2018
31
Systemic Lupus Erythematosus, Sjögren Syndrome, and Mixed Connective Tissue Disease in Children and Adolescents. ( 30031495 )
2018
32
Interstitial Cystitis: An uncommon revelation in primitive Sjögren syndrome. ( 30325002 )
2018
33
Type I Interferon Signaling Is Required for Dacryoadenitis in the Nonobese Diabetic Mouse Model of Sjögren Syndrome. ( 30347820 )
2018
34
Dry skin manifestations in Sjögren syndrome and atopic dermatitis related to aberrant sudomotor function in inflammatory allergic skin diseases. ( 30104151 )
2018
35
Case of primary Sjogren's syndrome preceded by dystonia. ( 29866668 )
2018
36
An unusual manifestation of Sjögren syndrome encephalitis. ( 30170935 )
2018
37
Fibrous histiocytoma as first presentation in systemic lupus erythematosus and sero-positive Sjögren's syndrome. ( 30094396 )
2018
38
Isolated end-stage renal disease in Sjögren's syndrome due to immune complex mediated glomerulonephritis. ( 30524747 )
2018
39
A patient presenting with isolated hematuria and renal dysfunction as rare manifestation of cryoglobulinemic glomerulonephritis in the course of autoimmune diseases including Sjögren's syndrome. ( 29671215 )
2018
40
Sjögren's Syndrome, Non-Sjögren's Syndrome, and Graft-Versus-Host Disease Related Dry Eye. ( 30481809 )
2018
41
Helicobacter pylori infection in Sjögren's syndrome:Co-incidence or causality? ( 30421681 )
2018
42
Association between Helicobacter pylori infection and Sjögren syndrome: A meta-analysis. ( 30544455 )
2018
43
Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren's syndrome: Idiopathic no more? ( 29984151 )
2018
44
Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population. ( 29465360 )
2018
45
Syphilitic Interstitial Keratitis in a Patient Diagnosed With Sjögren's Syndrome. ( 29280828 )
2018
46
A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population. ( 30242640 )
2018
47
Severity of Sjögren's Syndrome Keratoconjunctivitis Sicca Increases with Increased Percentage of Conjunctival Antigen-Presenting Cells. ( 30223431 )
2018
48
Phenotypic features and predictors of the clinical severity of keratoconjunctivitis sicca and salivary gland dysfunction in patients with Sjögren's syndrome: a longitudinal analysis of the Korean Initiative of primary Sjögren's Syndrome (KISS) cohort. ( 30475093 )
2018
49
Comparative Assessment of Hand Joint Ultrasound Findings in Symptomatic Patients with Systemic Lupus Erythematosus and Sjögren's Syndrome: A Pilot Study. ( 30401509 )
2018
50
Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus. ( 30416033 )
2018

Variations for Sjogren Syndrome

Expression for Sjogren Syndrome

Search GEO for disease gene expression data for Sjogren Syndrome.

Pathways for Sjogren Syndrome

Pathways related to Sjogren Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Toll-like receptor signaling pathway hsa04620
2 JAK-STAT signaling pathway hsa04630

Pathways related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.74 B2M FASLG SPTAN1 TNFSF13B TNFSF4 TRIM21
2 11.77 B2M FASLG TNFSF13B TNFSF4
3 10.28 FASLG TNFSF13B TNFSF4

GO Terms for Sjogren Syndrome

Cellular components related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 APOH B2M FASLG HSPG2 LTF SIL1
2 cell surface GO:0009986 9.65 APOH B2M FASLG LTF TNFSF4
3 ribonucleoprotein complex GO:1990904 9.5 SSB TRIM21 TROVE2
4 specific granule lumen GO:0035580 9.13 B2M LTF SPTAN1
5 tertiary granule lumen GO:1904724 8.8 B2M LTF SPTAN1

Biological processes related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.33 APOH FASLG HSPG2
2 positive regulation of T cell cytokine production GO:0002726 8.96 B2M TNFSF4
3 tumor necrosis factor-mediated signaling pathway GO:0033209 8.8 FASLG TNFSF13B TNFSF4

Molecular functions related to Sjogren Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 8.8 FASLG TNFSF13B TNFSF4

Sources for Sjogren Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....